Company intelligence / Profile preview

Preferred Cell Systems

Colorado, United States

Ownership: Private
Development stage: Other

Overview

The company offers commercial, instrument-based assays and cell culture media for research and cellular therapy manufacturing, recently transitioning from traditional colony-forming assays to advanced automated readouts. Its technology underpins standardized, reproducible stem/immune cell analytics and expansion for drug development, toxicity, and cellular therapy applications. It reported substantial kit sales growth (200% YoY in 2024) and is regarded as a key supplier in the field.

Therapeutic areas: HematologyImmunology
Modalities: Cell therapyReagentAssay kitBiologicDevice
Industry: Drug Discovery Services

Beyond the preview

Go deeper on Preferred Cell Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Preferred Cell Systems.

Explore the full profile